HC Wainwright Reiterates “Buy” Rating for Bright Minds Biosciences (NASDAQ:DRUG)
HC Wainwright reissued their buy rating on shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $85.00 price objective on the stock. DRUG has been the subject of several other research reports. Cantor Fitzgerald began coverage on shares of […]
HC Wainwright reissued their buy rating on shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $85.00 price objective on the stock. DRUG has been the subject of several other research reports. Cantor Fitzgerald began coverage on shares of […]
